Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
high-dose
human
influenza
influenza vaccines
Journal
Reviews in medical virology
ISSN: 1099-1654
Titre abrégé: Rev Med Virol
Pays: England
ID NLM: 9112448
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
16
01
2022
received:
18
11
2021
accepted:
18
01
2022
medline:
8
5
2023
pubmed:
5
2
2022
entrez:
4
2
2022
Statut:
ppublish
Résumé
This review sought to assess the efficacy, effectiveness and safety of high-dose inactivated influenza vaccines (HD-IIV) for the prevention of laboratory-confirmed influenza in individuals aged 18 years or older. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs) were included. The search returned 28,846 records, of which 36 studies were included. HD-IIV was shown to have higher relative vaccine efficacy in preventing influenza compared with standard-dose influenza vaccines (SD-IIV3) in older adults (Vaccine effectiveness (VE) = 24%, 95% CI 10-37, one RCT). One NRSI demonstrated significant effect for HD-IIV3 against influenza B (VE = 89%, 95% CI 47-100), but not for influenza A(H3N2) (VE = 22%, 95% CI -82 to 66) when compared with no vaccination in older adults. HD-IIV3 showed significant relative effect compared with SD-IIV3 for influenza-related hospitalisation (VE = 11.8%, 95% CI 6.4-17.0, two NRSIs), influenza- or pneumonia-related hospitalisation (VE = 13.7%, 95% CI 9.5-17.7, three NRSIs), influenza-related hospital encounters (VE = 13.1%, 95% CI 8.4-17.7, five NRSIs), and influenza-related office visits (VE = 3.5%, 95% CI 1.5-5.5, two NRSIs). For safety, HD-IIV were associated with significantly higher rates of local and systemic adverse events compared with SD-IIV (combined local reactions, pain at injection site, swelling, induration, headache, chills and malaise). From limited data, compared with SD-IIV, HD-IIV were found to be more effective in the prevention of laboratory-confirmed influenza, for a range of proxy outcome measures, and associated with more adverse events.
Substances chimiques
Influenza Vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2330Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
European Centre for Disease Prevention and Control (ECDC). Factsheet About Seasonal Influenza; 2019. https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet
Scorza FB, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines: shifting to better vaccines. Vaccine. 2016;34(26):2926-2933.
World Health Organization (WHO). Seasonal Influenza; 2018. https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal
Nielsen J, Vestergaard LS, Richter L, et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered? Clin Microbiol Infect. 2019;25(10):1266-1276.
Cassini A, Colzani E, Pini A, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill. 2018;23(16):1-20.
Paules CI, Sullivan SG, Subbarao K, Fauci AS. Chasing seasonal influenza-the need for a universal influenza vaccine. N Engl J Med. 2018;378(1):7-9.
Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza vaccines. Hum Vaccines Immunother. 2018;14(3):550-564.
Boraschi D, Italiani P. Immunosenescence and vaccine failure in the elderly: strategies for improving response. Immunol Lett. 2014;162(1):346-353.
Centers for Disease Control and Prevention (CDC). Fluzone High-Dose Seasonal Influenza Vaccine; 2019. https://www.cdc.gov/flu/prevent/qa_fluzone.htm
Wells C, Grobelna A. High Dose Influenza Vaccine for Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. CADTH Rapid Response Report: Summary with Critical Appraisal; 2019.
Wilkinson K, Wei Y, Szwajcer A, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis. Vaccine. 2017;35(21):2775-2780.
European Centre for Disease Prevention and Control (ECDC). Types of Seasonal Influenza Vaccine; 2019. https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/types-of-seasonal-influenza-vaccine
Jordan K, O Murchu E, Al E. Systematic Review of the Efficacy, Effectiveness and Safety of Cell-Based Seasonal Influenza Vaccines for the Prevention of Laboratory-Confirmed Influenza in Individuals ≥18 Years of Age. 2021. Manuscript under review.
O Murchu E, Comber L, Al E. Systematic Review of the Efficacy, Effectiveness and Safety of MF59® Adjuvanted Seasonal Influenza Vaccines for the Prevention of Laboratory-Confirmed Influenza in Individuals ≥18 Years of Age. 2021. Manuscript under review.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269.
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. Br Med J. 2011;343:d5928.
Higgins J, Wells G. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane; 2011.
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Br Med J. 2016;355:i4919.
IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14(1):25.
Thorlund K, Wetterslev J, Awad T, Thabane L, Gluud C. Comparison of statistical inferences from the DerSimonian-Laird and alternative random-effects model meta-analyses-an empirical assessment of 920 Cochrane primary outcome meta-analyses. Res Synthesis Methods. 2011;2(4):238-253.
Bender R, Friede T, Koch A, et al. Methods for evidence synthesis in the case of very few studies. Res Synthesis Methods. 2018;9(3):382-392.
Jackson D, Turner R. Power analysis for random-effects meta-analysis. Res Synthesis Methods. 2017;8(3):290-302.
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394.
Schünemann HJ, Cuello C, Akl EA, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105-114.
DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635-645. https://doi.org/10.1056/NEJMoa1315727. Cited in: Pubmed; PMID CN-00996670.
Diaz Granados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. J Am Geriatrics Soc. 2014;62:S37-S331. https://doi.org/10.1111/jgs.12870
DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine. 2015;33(38):4988-4993. https://doi.org/10.1016/j.vaccine.2015.07.006
Zimmerman RK, Nowalk MP, Chung J, et al. 2014-2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis. 2016;63(12):1564-1573. https://doi.org/10.1093/cid/ciw635
Butler AM, Layton JB, Dharnidharka VR, Sahrmann JM, Weber DJ, McGrath LJ. Comparative effectiveness of high dose versus standard-dose influenza vaccine among patients on chronic hemodialysis. Pharmacoepidemiol Drug Saf. 2019;28:239. https://doi.org/10.1002/pds.4864
Izurieta HS, Chillarige Y, Kelman J, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017-2018. J Infect Dis. 2019;220(8):1255-1264. https://doi.org/10.1093/infdis/jiy716
Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015;15(3):293-300. https://doi.org/10.1016/S1473-3099(14)71087-4
Lu Y, Chillarige Y, Izurieta H, et al. Effect of age on relative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries ages 65 years and older. Pharmacoepidemiol Drug Saf. 2019;28:239-240. https://doi.org/10.1002/pds.4864
Richardson DM, Medvedeva EL, Roberts CB, Linkin DR. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis. 2015;61(2):171-176. https://doi.org/10.1093/cid/civ261
Shay DK, Chillarige Y, Kelman J, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014. J Infect Dis. 2017;215(4):510-517. https://doi.org/10.1093/infdis/jiw641
Young-Xu Y, Van Aalst R, Mahmud SM, et al. Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among veterans health administration patients. J Infect Dis. 2018;217(11):1718-1727. https://doi.org/10.1093/infdis/jiy088
Young-Xu Y, Snider JT, van Aalst R, et al. Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method. Vaccine. 2019;37(11):1484-1490. https://doi.org/10.1016/j.vaccine.2019.01.063
Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults >/=65years of age: a phase 3 randomized clinical trial. Vaccine. 2019;37(39):5825-5834. https://doi.org/10.1016/j.vaccine.2019.08.016. Cited in: Pubmed; PMID 31431411.
Colmegna I, Useche ML, Rodriguez K, et al. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial. Lancet Rheumatology. 2020;2(1):e14-e23. https://doi.org/10.1016/S2665-9913(19)30094-3
Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine. 2007;25(44):7656-7663. https://doi.org/10.1016/j.vaccine.2007.08.042. Cited in: Pubmed; PMID CN-00619853.
Cowling BJ, Perera R, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. 71. Clin Infect Dis. 2019:1704-1714. https://doi.org/10.1093/cid/ciz1034. Cited in: Pubmed; PMID CN-02052271.
Diazgranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Effect of previous-year vaccination on the efficacy, immunogenicity, and safety of high-dose inactivated influenza vaccine in older adults. Clin Infect Dis. 2016;62(9):1092-1099. https://doi.org/10.1093/cid/ciw085
DiazGranados CA, Saway W, Gouaux J, et al. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age. Vaccine. 2015;33(51):7188-7193. https://doi.org/10.1016/j.vaccine.2015.10.131
Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200(2):172-180. https://doi.org/10.1086/599790
Halasa NB, Savani BN, Asokan I, et al. Randomized double-blind study of the safety and immunogenicity of standard-dose trivalent inactivated influenza vaccine versus high-dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplantation patients. Biol Blood Marrow Transpl. 2016;22(3):528-535. https://doi.org/10.1016/j.bbmt.2015.12.003. Cited in: Pubmed; PMID 26705931.
Jamshed S, Walsh EE, Dimitroff LJ, Santelli JS, Falsey AR. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: a pilot randomized clinical trial. Vaccine. 2016;34(5):630-635. https://doi.org/10.1016/j.vaccine.2015.12.037
Keipp Talbot H, Dunning AJ, Robertson CA, Landolfi VA, Greenberg DP, DiazGranados CA. Gastrointestinal events in high-dose vs standard-dose influenza vaccine recipients. Open Forum Infect Dis. 2018;5(6). https://doi.org/10.1093/ofid/ofy115
Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Archives Intern Med. 2006;166(10):1121-1127. https://doi.org/10.1001/archinte.166.10.1121
McKittrick N, Frank I, Jacobson JM, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in hiv-infected persons. a single-center, parallel, randomized trial. Ann Intern Med. 2013;158(1):19-26. https://doi.org/10.7326/0003-4819-158-1-201301010-00005
Nace DA, Lin CJ, Ross TM, Saracco S, Churilla RM, Zimmerman RK. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. J Infect Dis. 2015;211(12):1915-1924. https://doi.org/10.1093/infdis/jiu622
Natori Y, Shiotsuka M, Slomovic J, et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin Infect Dis. 2018;66(11):1698-1704. https://doi.org/10.1093/cid/cix1082
Noh JY, Jang YS, Lee SN, et al. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults. Vaccine. 2019;37(36):5171-5176. https://doi.org/10.1016/j.vaccine.2019.07.076
Pillet S, Couillard J, Trepanier S, et al. Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-two randomized Phase II clinical trials in 18 to 49 and 50 years old adults. PLoS ONE. 2019;14(6):e0216533. https://doi.org/10.1371/journal.pone.0216533. Cited in: Pubmed; PMID CN-01963534.
Sanchez L, Matsuoka O, Inoue S, et al. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial. Hum Vaccines Immunother. 2019;16:858-866. https://doi.org/10.1080/21645515.2019.1677437
Tsang P, Gorse GJ, Strout CB, et al. Immunogenicity and safety of Fluzone((R)) intradermal and high-dose influenza vaccines in older adults >/=65 years of age: a randomized, controlled, phase II trial. Vaccine. 2014;32(21):2507-2517. https://doi.org/10.1016/j.vaccine.2013.09.074. Cited in: Pubmed; PMID 24120672.
Arya DP, Said MA, Izurieta HS, et al. Surveillance for Guillain-Barre syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries. Vaccine. 2019;37(43):6543-6549. https://doi.org/10.1016/j.vaccine.2019.08.045. Cited in: Pubmed; PMID 31515146.
Branagan AR, Duffy E, Albrecht RA, et al. Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial. Clin Lymphoma, Myeloma Leukemia. 2017;17:296-304. https://doi.org/10.1016/j.clml.2017.02.025. Cited in: Pubmed; PMID CN-01336424.
Chong CR, Park VJ, Cohen B, Postow MA, Wolchok JD, Kamboj M. Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis. 2020;70(2):193-199. https://doi.org/10.1093/cid/ciz202
Kaka AS, Filice GA, Myllenbeck S, Nichol KL. Comparison of side effects of the 2015-2016 high-dose, inactivated, trivalent influenza vaccine and standard dose, inactivated, trivalent influenza vaccine in adults >=65 years. Open Forum Infect Dis. 2017;4(1). https://doi.org/10.1093/oid/ofx001. Cited in: Pubmed; PMID CN-01371821.
Strowd RE, Russell G, Hsu FC, et al. Immunogenicity of high-dose influenza vaccination in patients with primary central nervous system malignancy. Neuro-Oncology Pract. 2018;5(3):176-183. https://doi.org/10.1093/nop/npx035
Gravenstein S, Davidson HE, Taljaard M, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med. 2017;5(9):738-746. https://doi.org/10.1016/S2213-2600(17)30235-7
van Aalst R, Gravenstein S, Mor V, et al. Comparative effectiveness of high dose versus adjuvanted influenza vaccine: a retrospective cohort study. Vaccine. 2020;38(2):372-379. https://doi.org/10.1016/j.vaccine.2019.09.105
Izikson R, Leffell DJ, Bock SA, et al. Randomized comparison of the safety of Flublok((R)) versus licensed inactivated influenza vaccine in healthy, medically stable adults >/= 50 years of age. Vaccine. 2015;33(48):6622-6628. https://doi.org/10.1016/j.vaccine.2015.10.097. Cited in: Pubmed; PMID 26529070.
World Health Organization. Evaluation of Influenza Vaccine Effectiveness: A Guide to the Design and Interpretation of Observational Studies. World Health Organization; 2017.
Lee JK, Lam GK, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expet Rev Vaccine. 2018;17(5):435-443.
Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine. 2007;25(39-40):6852-6862.
Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36-44.
Teljeur C, Comber L, Al E. Challenges Encountered During the Systematic Review of Newer and Enhanced Influenza Vaccines and Recommendations for the Future Manuscript Under Review. 2021.
Vardeny O, Kim K, Udell JA, et al. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial. JAMA. 2021;325(1):39-49.
Balasubramani G, Choi WS, Nowalk MP, et al. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19. Vaccine. 2020;38(42):6562-6569.
Machado MAdA, Moura CS, Abrahamowicz M, Ward BJ, Pilote L, Bernatsky S. Relative effectiveness of influenza vaccines in elderly persons in the United States, 2012/2013-2017/2018 seasons. NPJ Vaccines. 2021;6(1):1-6.
Paudel M, Mahmud S, Buikema A, et al. Relative vaccine efficacy of high-dose versus standard-dose influenza vaccines in preventing probable influenza in a Medicare Fee-for-Service population. Vaccine. 2020;38(29):4548-4556.
Young-Xu Y, Snider JT, Mahmud SM, et al. High-dose influenza vaccination and mortality among predominantly male, white, senior veterans, United States, 2012/13 to 2014/15. Euro Surveill. 2020;25(19):1900401.
Levin MJ, Divino V, Shah D, et al. Comparing the clinical and economic outcomes associated with adjuvanted versus high-dose trivalent influenza vaccine among adults Aged≥ 65 Years in the US during the 2019-20 influenza season-a retrospective cohort analysis. Vaccines. 2021;9(10):1146.
Boikos C, Imran M, Nguyen VH, Ducruet T, Sylvester GC, Mansi JA. Effectiveness of the adjuvanted influenza vaccine in older adults at high risk of influenza complications. Vaccines. 2021;9(8):862.
Pelton SI, Divino V, Postma MJ, et al. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season. Vaccine. 2021;39(17):2396-2407.
Pelton SI, Divino V, Shah D, et al. Evaluating the relative vaccine effectiveness of adjuvanted trivalent influenza vaccine compared to high-dose trivalent and other egg-based influenza vaccines among older adults in the US during the 2017-2018 influenza season. Vaccines. 2020;8(3):446.
Izurieta HS, Chillarige Y, Kelman J, et al. Relative effectiveness of influenza vaccines among the United States elderly, 2018-2019. J Infect Dis. 2020;222(2):278-287.
Lipsitch M. Challenges of Vaccine Effectiveness and Waning Studies. Oxford University Press US; 2019.
I-MOVE Project. I-MOVE Europe 2019. 2019. https://sites.google.com/site/epiflu/Home
Jefferson T, Di Pietrantonj C, Debalini M, Rivetti A, Demicheli V. Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. Br Med J. 2009;338:b354.
Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018(2).